Combined use of 0.1% fluorometholone and meibomian gland expression improves symptoms of moderate and severe dry eye disease, even in patients with systemic immune disease

Combined use of 0.1% fluorometholone and meibomian gland expression improves symptoms of moderate and severe dry eye disease, even in patients with systemic immune disease

This study prospectively evaluated the effect of 0.1% fluorometholone (FML) combined with meibomian gland expression (MGX) on dry eye disease (DED) and meibomian gland dysfunction (MGD).The study included 48 patients (96 eyes) with moderate to severe DED. The patients were treated with topical FML a...

Full description

Bibliographic Details
Main Authors: Xuming Guo, Aipeng Li, Yi Fan, Yanru Yu, Wenhui Guo, Ying Jie
Format: Article
Language:English
Published: Taylor & Francis Group 2019-01-01
Series:Biotechnology & Biotechnological Equipment
Subjects:
fluorometholone
meibomian gland dysfunction
meibomian gland expression
Online Access:http://dx.doi.org/10.1080/13102818.2019.1656107

Internet

http://dx.doi.org/10.1080/13102818.2019.1656107

Similar Items